The UK Government has signed a long-term partnership agreement with the German company BioNTech to support clinical trials for personalised mRNA cancer immunotherapies. This partnership could mean access to precision cancer treatment for up to 10 000 patients in the UK by 2030 and includes plans for new facilities and staff to support the initiative.
[News] UK–BioNTech partnership for mRNA cancer vaccines
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy